A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)

Overview

Chronic obstructive pulmonary disease (COPD) is characterized by a progressive decline in lung function and increased symptoms such as breathlessness/dyspnoea, cough and expectoration. Even though subjective in nature, the symptomatology of COPD and mainly that of breathlessness/dyspnoea has been studied with the use of objective measurement tools. Taking into consideration that the symptoms experienced by the patient who suffers from a progressive disease such as COPD can only be perceived and interpreted by the patient him- or herself, and thus difficult to be quantified, COPD remains a challenge in clinical research. Therefore, there is a need to carry out qualitative studies that will provide insight into the wide spectrum of COPD symptomatology from the patient's perspective. In addition, a further mapping of the impact that COPD symptoms' perception has on a patient's life is required, as well as of the different pathways through which symptoms' perception is interpreted regarding the limitations of daily living activities, and the subsequent impact on disease management. The more the physician learns on the embodied experience of COPD, the better he/she may assist the patient in achieving optimal COPD management. Thus this cross-sectional observational study was designed aiming to obtain these data. Specifically, the study aims to evaluate the most frequently used words by the patients and the physicians to express the symptoms of COPD as well as the limitation of activities that it causes.

Full Title of Study: “A Cross Sectional Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease and the Limitations of Patients’ Activities in Primary Care.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: March 2011

Arms, Groups and Cohorts

  • 1
    • Patients with Chronic Obstructive Pulmonary Disease

Clinical Trial Outcome Measures

Primary Measures

  • Words used by the patients and the physicians to express the symptoms of COPD as well as the limitations of patients’ daily living activities caused by COPD.
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)

Secondary Measures

  • Age
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Gender
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Place of residence
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Marital status
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Native language
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Educational level
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Occupation
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Co-morbidities
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Years / months since COPD diagnosis and years with COPD symptoms
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Smoking history
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Number of exacerbations during the last year
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Current therapy
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • CCQ score
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Compliance with therapy
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Actions/therapeutic recommendations by the physician associated with each chosen word that express the chronic daily symptoms
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Scale for the assessment of the severity of the relevant symptoms
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Actions/therapeutic recommendations by the physician when any of the symptoms worsen
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Severity scale regarding how the patient experiences each of the chosen words that express the chronic daily symptoms
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Related actions initiated by the patient regarding chronic daily symptoms
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)
  • Related actions initiated by the patient when the symptoms worsen.
    • Time Frame: End of recruitment (estimated timeframe :2.5 months)

Participating in This Clinical Trial

Inclusion Criteria

  • Aged 45-75 years – Current or former smokers – Known history of COPD for at least 6 months before enrolment into the study documented by spirometry (FEV1 /FVC <70%) – Patients with stable COPD (no exacerbation within the last month before enrolment into the study) under treatment with a long-acting inhaled bronchodilator (LABA and/or LAMA) alone or in combination with an inhaled corticosteroid – Written consent for participation in the study – Patients who are able to complete by themselves in Greek a questionnaire on COPD. Exclusion Criteria:

  • Patients with diagnosed Asthma – Patients with any psychiatric, neurological or other disorder render them unable to complete the COPD questionnaire by themselves – The patient participates in another study.

Gender Eligibility: All

Minimum Age: 45 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Panagiotis Pontikis, Study Director,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.